PTC Therapeutics Inc [PTCT] stock is trading at $68.11, up 1.13%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The PTCT shares have gain 1.96% over the last week, with a monthly amount glided 9.84%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
PTC Therapeutics Inc [NASDAQ: PTCT] stock has seen the most recent analyst activity on October 20, 2025, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $73. Previously, Truist started tracking the stock with Buy rating on June 17, 2025, and set its price target to $80. On May 09, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $68 on the stock. Citigroup upgraded its rating to a Neutral but stick to its price target of $40 on May 07, 2025. BofA Securities upgraded its rating to a Neutral and raised its price target to $55 on March 11, 2025. Scotiabank started tracking with a Sector Perform rating for this stock on March 07, 2025, and assigned it a price target of $55. In a note dated December 13, 2024, Morgan Stanley upgraded an Overweight rating on this stock and boosted its target price from $45 to $67.
PTC Therapeutics Inc [PTCT] stock has fluctuated between $35.95 and $69.48 over the past year. Currently, Wall Street analysts expect the stock to reach $73.5 within the next 12 months. PTC Therapeutics Inc [NASDAQ: PTCT] shares were valued at $68.11 at the most recent close of the market. An investor can expect a potential return of 7.91% based on the average PTCT price forecast.
Analyzing the PTCT fundamentals
PTC Therapeutics Inc [NASDAQ:PTCT] reported sales of 1.76B for the trailing twelve months, which represents a drop of -4.19%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.41%, Pretax Profit Margin comes in at 0.38%, and Net Profit Margin reading is 0.36%. To continue investigating profitability, this company’s Return on Assets is posted at 0.24, Equity is -0.99 and Total Capital is 0.36. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.88.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 66.87 points at the first support level, and at 65.64 for the second support level. However, for the 1st resistance point, the stock is sitting at 69.61, and for the 2nd resistance point, it is at 71.12.
Ratios To Look Out For
For context, PTC Therapeutics Inc’s Current Ratio is 3.62. In addition, the Quick Ratio stands at 3.57 and the Cash Ratio stands at 1.62. Considering the valuation of this stock, the price to sales ratio is 3.07 and price to earnings (TTM) ratio is 9.77.
Transactions by insiders
Recent insider trading involved Reeve Emma, Director, that happened on Oct 30 ’25 when 15666.0 shares were purchased. EXEC. VP AND CLO, Boulding Mark Elliott completed a deal on Oct 07 ’25 to sell 3375.0 shares. Meanwhile, Director Reeve Emma sold 25562.0 shares on Oct 03 ’25.
